GlassScriptPhysician profile
Chelsea E Odil
NPI 1922493550
$4,498.97
in general payments reported to CMS, 2019-2025
16 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $814 · 2023: $1,872 · 2024: $1,144 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,093.43 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $856.60 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $482.89 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $475.43 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $434.76 | 2023-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $417.29 | 2021-2024 | Rexulti, Nuedexta |
| Bausch Health US, LLC | $126.77 | 2022-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $116.35 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $106.85 | 2022-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $74.83 | 2023-2024 | Trintellix |
| Lundbeck LLC | $72.18 | 2022-2025 | Rexulti |
| Noven Therapeutics, LLC | $65.85 | 2024 | Secuado, Xelstrym |
| Vanda Pharmaceuticals INC. | $52.19 | 2024 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $48.82 | 2023 | Austedo Xr |
| Tris Pharma INC | $46.85 | 2023-2024 | Dyanavel Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $27.88 | 2022-2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Odil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.